The U.S. Food and Drug Administration has revised the label on the drug , manufactured by Sanofi-Aventis , a Paris based pharmaceutical company. The change will reflect that there is a doubling health risk, including death, for patients with permanent atrial fibrillation. The FDA said, for these patients, the drug can and will double the rate of cardiovascular death, stroke and .

Multaq, known chemically as dronedarone, is still safe to treat patients with brief bouts of irregular heart rhythms. However, the stresses physicians must monitor the heart rhythms of patient’s being administered Multaq, at least once every three months.

Previous ArticleRiata ICD Leads Next ArticleVideo Page 2
Verdicts and Settlements
Contact Us

Subscribe Now!

[contact-form-7 404 "Not Found"]

Follow Us!

Unsafe Drugs has numerous resources on drug side effects,nutritional supplements, vitamins, and health products.

Site best viewed in Google Chrome, Firefox, Opera, Safari, IE browsers